AzTrials
AzTrials

Coronary Artery DiseaseLUNAR-CCTANCT02953613

LipiScan- Ultrasound INterrogation of Atherosclerotic Coronary Arteries:

An observational study of Coronary Artery Disease and Atherosclerosis, run by Corewell Health East at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The goal of this study is to correlate both plaque and % lipid core content assessed by NIRS-IVUS (Imaging technique) to plaque burden and % lipid core content in coronary computerized tomographic angiography (CCTA) completed at 1 week in non-culprit coronary arteries. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coronary Artery Disease, Atherosclerosis
What is being tested?
NIRS/IVUS
Type of treatment
Medical device
How many people
7 participants
Where
1 siteUnited States
Study dates
28 Apr 2016to 20 Nov 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients presenting to Beaumont Hospital for elective invasive coronary angioplasty and possible percutaneous intervention

Who may be able to join

  • Patients with stable ischemic heart disease or ACS undergoing cardiac catheterization and possible PCI of a culprit lesion
  • The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent approved by the Institutional Review Board.
  • The study patient agrees to comply with all required post-procedure follow up.
  • Patient age 18-89 years old

Who cannot join

  • STEMI within the prior 24 hours
  • Cardiogenic shock or hypotension needing inotropes or hemodynamic support device
  • Intra-procedural complication (perforation or a complication that would necessitate immediate-unplanned revascularization) during index PCI procedure
  • History of CABG
  • Subject life expectancy less than 2 years at time of index catheterization
  • Pregnant or unknown pregnancy status
Show all 11Show fewer
  • Psychological unsuitability or extreme claustrophobia
  • Currently participating in another investigational cardiac device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials
  • Inability to tolerate beta blockers
  • Atrio-ventricular block (grade II-III), prolonged QT interval or sick sinus syndrome
  • Renal insufficiency (creatinine ≥ 1.6 and/or, GFR < 60 ml/min) or renal failure requiring dialysis

Trial locations and contacts

1 site in 1 country.

United States1 site
  • William Beaumont Hospital

    Royal Oak, Michigan, 48073

Other trials in United States

About this study

Official title: LipiScan- Ultrasound INterrogation of Atherosclerotic Coronary Arteries: Correlations With Non-invasive Coronary Computer Tomographic Angiography. (LUNAR-CCTA Study)

The goal of this study is to correlate both plaque and % lipid core content assessed by NIRS-IVUS (Imaging technique) to plaque burden and % lipid core content in coronary computerized tomographic angiography (CCTA) completed at 1 week in non-culprit coronary arteries.

Read the detailed description

This is a prospective single center study that will enroll 200 patients undergoing clinically indicated cardiac catheterization for stable ischemic heart disease or unstable chest pain, who are also undergoing NIRS-IVUS direct coronary imaging of a culprit lesion based on routine clinical indications. The NIRS/IVUS catheter uses near-infrared light (red laser light) and intravascular ultrasound (sound waves) to identify fatty plaques in the coronary artery. Standard angiography, near-infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS) are three widely used clinical methods to image narrowing within the coronary arteries at the time of cardiac catheterization.

Independently from this study, patients have agreed to a cardiac catheterization (angiogram - an x-ray picture of the heart) and possible angioplasty procedure and/or stenting as part of clinical care. During the cardiac catheterization if the blockage is bad enough an inflatable balloon attached to the end of a thin tube (called a catheter) is positioned in the narrowed part of the coronary artery. The balloon is then inflated, which opens the artery so that blood can flow more easily. After the balloon angioplasty procedure, a stent may be placed in the coronary artery. A stent is an expandable metal tube that helps to hold the artery open so that blood can continue to flow through the artery.

If the doctor determines that there are other blockages of indeterminate severity (≥20%-≤70% blockage) that require NIRS/IVUS assessment to better assess the severity of the blockage or that angioplasty and/or stenting is necessary the NIRS/IVUS catheter will be used. If severe non-culprit blockages are incidentally identified, they may be treated at the discretion of the operator. After the invasive coronary catheterization patients will follow Beaumonts standard post procedureal treatment guidlines.

Between one day and one week after the invasive catheterization patients will return for a research related non-invasive coronary Cat scan. A coronary Cat scan will be repeated at 24 months (2 years) to assess any of the blockages of indeterminate severity that were identified during your initial invasive cardiac catheterization. Upon arrival for Cat scan a nurse will ask the patient a few questions, insert a small tube in one of the patients arm veins. Blood will be drawn from the small tub and kidney function will be assessed. All Cat scans will be completed under Beaumont Hospital Institutional guidelines for coronary Cat scans. If significant blockages are identified, the patient may be notified to complete additional testing, which may include a stress test or a coronary angiogram. If other non-cardiac incidental findings are noted that require additional clinical or imaging follow up, the patient and the primary care physician will be notified.

A study doctor, nurse, or research coordinator will follow-up with each patient by phone six times over five years while participating in the registry. Phone calls will be performed at the following intervals from the date of the index procedure: 6 months (± 14 days); 12 months (± 30 days); 24 months (± 60 days); 36 months (± 60 days); 48 months (± 60 days); and 60 months (± 60 days) to ask patients how they are doing and to collect any major adverse cardiac events.

The Plan is for an enrollment period of two years.

Being tested
NIRS/IVUS
Keywords
Cardiac Catheterization, Cardiac intervention, coronary angiogram, coronary artery disease, atherosclerosis
Medical subject headings
Coronary Artery Disease, Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NIRS/IVUSDevice

    Also called Infraredx

    Cardiac catheterization using infraredx

Study groups in NCT02953613
Study groupRoleWhat they receive
Cardiac Catheterization with NIRS/IVUSCardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months
Receives: Device: NIRS/IVUS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To correlate blockages by NIRS-IVUS with CCTA

    To correlate both plaque burden and % lipid core content assessed by NIRS-IVUS to plaque burden and % lipid core content on coronary computerized tomographic angiography (CCTA) completed at 1 week in non-culprit coronary arteries.

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2016 (estimated)
  2. Study start28 Apr 2016
  3. Primary completion20 Nov 2017
  4. Study completion20 Nov 2017

Why it stopped: unable to identify sufficient eligible patients to meet enrollment goals

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02953613
Sponsor's protocol ID
2015-129
Acronym
LUNAR-CCTA
Status last verified
Aug 2021
First submitted
24 Aug 2016
Last updated
10 Aug 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Disease and Atherosclerosis, run by Corewell Health East at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 10 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: unable to identify sufficient eligible patients to meet enrollment goals). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To correlate blockages by NIRS-IVUS with CCTA (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in